Details of the BTS

General Information of Binding Target of SBP (BTS) (ID: ST00363)
BTS Name	T-cell surface glycoprotein CD3
Synonyms	CD3
BTS Type	Protein
Organism	Homo sapiens (Human)

Synthetic Binding Protein (SBP) Targeting This BTS

SBP Name	Highest Status	Mechanism	Affinity	Application	Details	Ref
Affimer anti-CD3/CD22 AVA-012	Research	Binder	N.A.	Cancers [ICD-11: 2D4Z]	SBP Info	[1]
Affimer anti-CD3/CD3E AVA-002	Research	Binder	N.A.	Cancers [ICD-11: 2D4Z]	SBP Info	[1]
BiTE Acapatamab	Phase I	Inhibitor	N.A.	Prostate cancer [ICD-11: 2C82.Z]	SBP Info	[2]
BiTE AMG-199	Phase I	Stimulator	N.A.	Metastatic gastric [ICD-11: 2D8Y]; Gastroesophageal junction cancer [ICD-11: 2B71.Z]	SBP Info	[2], [3]
BiTE AMG-211	Phase I; Discontinued	Stimulator	N.A.	GI adenocarcinoma [ICD-11: 2D40]	SBP Info	[4], [5]
BiTE AMG-427	Phase I	Inhibitor	N.A.	Acute myeloid leukaemia [ICD-11: XH8AA5]	SBP Info	[6], [2]
BiTE AMG-562	Phase I	Binder	N.A.	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5]; Follicular lymphoma [ICD-11: 2A80]; Mantle cell lymphoma [ICD-11: 2A85.5]	SBP Info	[2], [3]
BiTE AMG-673	Phase I; Suspended	Inhibitor	N.A.	Acute myeloid leukaemia [ICD-11: XH8AA5]	SBP Info	[2]
BiTE AMG-910	Phase I	Stimulator	N.A.	Gastric cancer [ICD-11: 2B72.Z]; Gastroesophageal Junction Cancer [ICD-11: 2B71.Z]	SBP Info	[2]
BiTE anti-CD19/CD3 AMG103	Research	Binder	N.A.	Cancers [ICD-11: 2D4Z]	SBP Info	[7]
BiTE anti-CD3/SV2B	Research	Binder	N.A.	Cancers [ICD-11: 2D4Z]	SBP Info	[8]
BiTE anti-EpCAM/CD3 MuS110	Research	Binder	N.A.	Breast cancer [ICD-11: 2C6Z]; Lung cancer [ICD-11: 2C25.Z]	SBP Info	[9], [10]
BiTE anti-TfR/CD3	Research	Binder	N.A.	Solid tumour/cancer [ICD-11: 2A00-2F9Z]	SBP Info	[11]
BiTE Blinatumomab	Marketed	Binder	N.A.	Burkitt-like lymphoma with 11q aberration [ICD-11: XH8NN2]	SBP Info	[12], [9], [13]
BiTE Eluvixtamab	Phase I	Inhibitor	N.A.	Acute myeloid leukaemia [ICD-11: XH8AA5]	SBP Info	[14], [2]
BiTE Etevritamab	Phase I; Discontinued	Stimulator	N.A.	Glioblastoma [ICD-11: XH7F82]	SBP Info	[2], [3], [4]
BiTE Pacanalotamab	Phase I	Binder	N.A.	Multiple myeloma [ICD-11: 2A83.Y]	SBP Info	[3], [15]
BiTE Pasotuxizumab	Phase I	Binder	N.A.	Metastatic castration-resistant prostate cancer [ICD-11: 2C82.Y]	SBP Info	[9], [16]
BiTE Pavurutamab	Phase I; Suspended	Inhibitor	N.A.	Prostate cancer [ICD-11: 2C82.Z]; Multiple myeloma [ICD-11: 2A83.Y]	SBP Info	[2]
BiTE Solitomab	Phase II	Inhibitor	Kd: 77 nM	Lung cancer [ICD-11: 2C25.Z]; Gastrointestinal cancer [ICD-11: 2C11.Z]	SBP Info	[9], [17]
BiTE Tarlatamab	Phase I	Inhibitor	N.A.	Small cell carcinoma of bronchus or lung [ICD-11: 2C25.1]; Prostate cancer [ICD-11: 2C82.Z]	SBP Info	[2]
DART anti-Beta-diketone/CD3 DART	Research	Binder	N.A.	Ovarian cancer [ICD-11: 2C73.Z]	SBP Info	[18]
DART anti-cadherin/CD3 153	Research	Binder	Kd: 15.6 nM	Cancers [ICD-11: 2D4Z]	SBP Info	[19]
DART anti-cadherin/CD3 20	Research	Binder	Kd: 5.2 nM	Cancers [ICD-11: 2D4Z]	SBP Info	[19]
DART anti-cadherin/CD3 30	Research	Binder	Kd: 13.6 nM	Cancers [ICD-11: 2D4Z]	SBP Info	[19]
DART anti-cadherin/CD3 33	Research	Binder	Kd: 18.3 nM	Cancers [ICD-11: 2D4Z]	SBP Info	[19]
DART anti-cadherin/CD3 34	Research	Binder	Kd: 21.9 nM	Cancers [ICD-11: 2D4Z]	SBP Info	[19]
DART anti-cadherin/CD3 35	Research	Binder	Kd: 23.2 nM	Cancers [ICD-11: 2D4Z]	SBP Info	[19]
DART anti-cadherin/CD3 PF-06671008	Research	Inhibitor	Kd: 0.18 nM	Solid tumour/cancer [ICD-11: 2A00-2F9Z]	SBP Info	[19]
DART anti-CD3 MGD015	Research	Binder	N.A.	Hematological malignancies [ICD-11: MG24.0Y]; Solid tumour/cancer [ICD-11: 2A00-2F9Z]	SBP Info	[20]
DART anti-FOLR1/CD3 DART	Research	Binder	N.A.	Ovarian cancer [ICD-11: 2C73.Z]	SBP Info	[18]
DART anti-GPA33/CD3 MGD007	Research	Binder	N.A.	Metastatic colorectal cancer [ICD-11: 2B91.Z]	SBP Info	[21]
DART anti-HIV Env/CD3 MGD014	Research	Binder	N.A.	Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]	SBP Info	[21]
DART Duvortuxizumab	Phase I; Discontinued	Binder	N.A.	B-cell hematological malignancies [ICD-11: 2B33.Y]	SBP Info	[21]
DART Flotetuzumab	Phase II	Binder	N.A.	Acute myeloid leukaemia [ICD-11: XH8AA5]; Myelodysplastic syndrome (MDS) [ICD-11: 2A3Z]	SBP Info	[9], [22]
DART Obrindatamab	Phase I; Discontinued	Binder	N.A.	B7-H3-positive tumors	SBP Info	[23]
Diabody anti-CEA x anti-CD3	Research	Binder	N.A.	Cancers [ICD-11: 2D4Z]	SBP Info	[24]
Diabody anti-ERBB1/CD3 hEx3	Research	Binder	N.A.	Imaging agent for patients with cancer; Cancers [ICD-11: 2D4Z]	SBP Info	[25], [26]
scFv anti-BHL clone B1	Research	Binder	N.A.	Ovarian cancer [ICD-11: 2C73.Z]	SBP Info	[27]
scFv anti-BHL clone B7	Research	Binder	N.A.	Ovarian cancer [ICD-11: 2C73.Z]	SBP Info	[27]
scFv anti-BHL clone B9	Research	Inhibitor	Kd: 64 nM	Hepatitis B virus infection [ICD-11: XN0GA]	SBP Info	[27]

References

1	Avacta. Product Development Pipeline. 2021.
2	Amgen. Product Development Pipeline. 2021.
3	The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 Jul 15;126(14):3192-3201.
4	Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. Mol Ther Oncolytics. 2019 Mar 23;14:38-56.
5	Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89 Zr-AMG211 Targeting CEA-Positive Tumors. Clin Cancer Res. 2018 Oct 15;24(20):4988-4996.
6	Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 2020 Sep;19(9):1875-1888.
7	Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front Immunol. 2020 May 7;11:762.
8	High throughput development of TCR-mimic antibody that targets survivin-2B 80-88/HLA-A*A24 and its application in a bispecific T-cell engager. Sci Rep. 2019 Jul 8;9(1):9827.
9	Recent advances in the development of novel protein scaffolds based therapeutics. Int J Biol Macromol. 2017 Sep;102:630-641.
10	Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res. 2008 Jan 1;68(1):143-51.
11	Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor. Front Immunol. 2019 Jun 21;10:1396.
12	Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011 May 15;317(9):1255-60.
13	DRUGBANK online. Blinatumomab
14	Harnessing T cells to fight cancer with BiTE? antibody constructs--past developments and future directions. Immunol Rev. 2016 Mar;270(1):193-208.
15	B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 Apr;34(4):985-1005.
16	Amgen. Product Development Pipeline. 2019.
17	MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006 Mar;43(8):1129-43.
18	Chemically Programmed Bispecific Antibodies in Diabody Format. J Biol Chem. 2016 Sep 9;291(37):19661-73.
19	Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer. Antibodies (Basel). 2016 Mar 4;5(1):6.
20	MacroGenics. MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015. Jun 28 2016.
21	MacroGenics. Product Development Pipeline. 2021.
22	KEGG DRUG Database. Flotetuzumab
23	MacroGenics. Data from MacroGenics' Preclinical Studies of MGD009 Presented at Keystone Symposia's Antibodies as Drugs (X2) Conference. Mar 7 2016.
24	Balanced secretion of anti-CEA G anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity. Gene Ther. 2017 Apr;24(4):208-214.
25	Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res. 2006 Jul 1;12(13):4036-42.
26	Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody. Protein Eng Des Sel. 2013 May;26(5):359-67.
27	Construction of a fully synthetic human scFv antibody library with CDR3 regions randomized by a split-mix-split method and its application. J Biochem. 2008 Nov;144(5):591-8.